Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma

Medical Oncology, 05/04/2012

Continuing therapy for more than one course and maintaining more than 60 % of 1–month relative dose intensity were very important in the prolongation of progression–free survival time regardless of the initial treatment doses.

Print Article Summary Cat 2 CME Report